WAT
Waters Corp /De/One customer — 10% of receivables (the three months ended April 4, 2026)
“The Company considers this to be a significant concentration of credit risk, as it accounts for greater than 10% of the Company’s accounts receivables for the three months ended April 4, 2026.”
Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 3, 4 and 5. Form 4 must be filed within two business days of the trade.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2026-06-30 | Jiang Wei |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
Represents common stock units received in lieu of cash payment of director fees pursuant to the Issuer's 1996 Non-Employee Director Deferred Compensation Plan. Common stock units are convertible into shares of the Issuer's common stock on a one-for-one basis upon distribution, which will occur automatically upon the Reporting Person's termination of service as a member of the Issuer's Board of Directors. |
Common Stock
|
67 |
| 2026-06-30 | Knight Heather |
Chief Commercial Officer |
Award↑
Filing footnotes — Common Stock (Direct)
Represents common stock units received in lieu of cash payment of director fees pursuant to the Issuer's 1996 Non-Employee Director Deferred Compensation Plan. Common stock units are convertible into shares of the Issuer's common stock on a one-for-one basis upon distribution, which will occur on January 1, 2027, pursuant to an election previously made by the Reporting Person. |
Common Stock
|
63 |
| 2026-06-24 | Carpio Robert L III |
SVP Waters Analytical Sciences |
Tax↓
Filing footnotes — Common Stock (Direct)
Represents shares of common stock withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of previously reported restricted stock units. |
Common Stock
|
189 |
| 2026-05-12 | Chaubal Amol |
SVP & Chief Financial Officer |
Tax↓
Filing footnotes — Common Stock (Direct)
Represents shares of common stock withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of previously reported restricted stock units. Includes 65.4519 shares of common stock acquired on March 31, 2026, pursuant to the Waters Corporation Amended and Restated 2009 Employee Stock Purchase Plan, in a transaction that was exempt pursuant to Rule 16b-3(c). |
Common Stock
|
239 |
| 2026-04-06 | Bennett Jianqing |
SVP Waters Adv. Diagnostics |
Tax↓
Filing footnotes — Common Stock (Direct)
Represents shares of common stock withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of previously reported restricted stock units. |
Common Stock
|
302 |
| 2026-03-31 | Jiang Wei |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
Represents common stock units received in lieu of cash payment of director fees pursuant to the Issuer's 1996 Non-Employee Director Deferred Compensation Plan. Common stock units are convertible into shares of the Issuer's common stock on a one-for-one basis upon distribution, which will occur on January 1, 2036, pursuant to an election previously made by the Reporting Person. |
Common Stock
|
64 |
| 2026-03-31 | Knight Heather |
Chief Commercial Officer |
Award↑
Filing footnotes — Common Stock (Direct)
Represents common stock units received in lieu of cash payment of director fees pursuant to the Issuer's 1996 Non-Employee Director Deferred Compensation Plan. Common stock units are convertible into shares of the Issuer's common stock on a one-for-one basis upon distribution, which will occur on January 1, 2027, pursuant to an election previously made by the Reporting Person. |
Common Stock
|
68 |
| 2026-03-16 | Jiang Wei |
Director |
Buy↑
|
Common Stock
|
500 |
| 2026-03-06 | FEARON RICHARD H |
Director |
Buy↑
Filing footnotes — Common Stock (Direct)
The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $305.84 to $306.49 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. |
Common Stock
|
1,000 |
| 2026-03-02 | Bennett Jianqing |
SVP Waters Adv. Diagnostics |
Tax↓
Filing footnotes — Common Stock (Direct)
Represents shares of common stock withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of previously reported performance stock units. |
Common Stock
|
410 |
| 2026-03-02 | Batra Udit |
Director, President and CEO |
Tax↓
Filing footnotes — Common Stock (Direct)
Represents shares of common stock withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of previously reported performance stock units. |
Common Stock
|
3,417 |
| 2026-03-02 | Chaubal Amol |
SVP & Chief Financial Officer |
Tax↓
Filing footnotes — Common Stock (Direct)
Represents shares of common stock withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of previously reported performance stock units. |
Common Stock
|
709 |
| 2026-02-25 | FEARON RICHARD H |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
Represents shares of common stock subject to restrictions that lapse with respect to 100% of the shares on February 9, 2027. |
Common Stock
|
23 |
| 2026-02-25 | Bennett Jianqing |
SVP Waters Adv. Diagnostics |
Award↑
Filing footnotes — Common Stock (Direct)
Represents restricted stock units ("RSUs"), which will vest in four equal annual installments, with the first such installment vesting on February 25, 2027, subject to the Reporting Person's continued service with the Issuer on each such vesting date. The RSUs are convertible into shares of the Issuer's common stock on a one-to-one basis upon vesting and settlement. |
Common Stock
|
986 |
| 2026-02-25 | Chaubal Amol |
SVP & Chief Financial Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The shares of common stock underlying this stock option will vest and become exercisable in four equal annual installments, with the first such installment vesting and becoming exercisable on February 25, 2027, subject to the Reporting Person's continued service with the Issuer on each such vesting date. |
Stock Option (Right to Buy)
|
7,125 |
| 2026-02-25 | Chaubal Amol |
SVP & Chief Financial Officer |
Award↑
Filing footnotes — Common Stock (Direct)
Represents restricted stock units ("RSUs"), which will vest in four equal annual installments, with the first such installment vesting on February 25, 2027, subject to the Reporting Person's continued service with the Issuer on each such vesting date. The RSUs are convertible into shares of the Issuer's common stock on a one-to-one basis upon vesting and settlement. |
Common Stock
|
1,455 |
| 2026-02-25 | BADDOUR LINDA |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
Represents shares of common stock subject to restrictions that lapse with respect to 100% of the shares on February 9, 2027. |
Common Stock
|
23 |
| 2026-02-25 | Knight Heather |
Chief Commercial Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
All of the shares of common stock underlying this stock option will vest and become exercisable on February 9, 2027. |
Stock Option (Right to Buy)
|
57 |
| 2026-02-25 | Fraser Claire |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
All of the shares of common stock underlying this stock option will vest and become exercisable on February 9, 2027. |
Stock Option (Right to Buy)
|
877 |
| 2026-02-25 | Knight Heather |
Chief Commercial Officer |
Award↑
Filing footnotes — Common Stock (Direct)
Represents shares of common stock subject to restrictions that lapse with respect to 100% of the shares on February 9, 2027. |
Common Stock
|
23 |
| 2026-02-25 | Fraser Claire |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
Represents shares of common stock subject to restrictions that lapse with respect to 100% of the shares on February 9, 2027. |
Common Stock
|
358 |
| 2026-02-25 | KUEBLER CHRISTOPHER A |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
All of the shares of common stock underlying this stock option will vest and become exercisable on February 9, 2027. |
Stock Option (Right to Buy)
|
57 |
| 2026-02-25 | Jiang Wei |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
All of the shares of common stock underlying this stock option will vest and become exercisable on February 9, 2027. |
Stock Option (Right to Buy)
|
57 |
| 2026-02-25 | Bennett Jianqing |
SVP Waters Adv. Diagnostics |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The shares of common stock underlying this stock option will vest and become exercisable in four equal annual installments, with the first such installment vesting and becoming exercisable on February 25, 2027, subject to the Reporting Person's continued service with the Issuer on each such vesting date. |
Stock Option (Right to Buy)
|
4,826 |
| 2026-02-25 | KUEBLER CHRISTOPHER A |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
Represents shares of common stock subject to restrictions that lapse with respect to 100% of the shares on February 9, 2027. |
Common Stock
|
23 |
| 2026-02-25 | Ornskov Flemming |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
Represents shares of common stock subject to restrictions that lapse with respect to 100% of the shares on February 9, 2027. |
Common Stock
|
336 |
| 2026-02-25 | Brennan Daniel J. |
EVP and CFO |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
All of the shares of common stock underlying this stock option will vest and become exercisable on February 9, 2027. |
Stock Option (Right to Buy)
|
57 |
| 2026-02-25 | FEARON RICHARD H |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
All of the shares of common stock underlying this stock option will vest and become exercisable on February 9, 2027. |
Stock Option (Right to Buy)
|
57 |
| 2026-02-25 | Jiang Wei |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
Represents shares of common stock subject to restrictions that lapse with respect to 100% of the shares on February 9, 2027. |
Common Stock
|
23 |
| 2026-02-25 | BADDOUR LINDA |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
All of the shares of common stock underlying this stock option will vest and become exercisable on February 9, 2027. |
Stock Option (Right to Buy)
|
57 |
| 2026-02-25 | Vergnano Mark |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
All of the shares of common stock underlying this stock option will vest and become exercisable on February 9, 2027. |
Stock Option (Right to Buy)
|
57 |
| 2026-02-25 | Brennan Daniel J. |
EVP and CFO |
Award↑
Filing footnotes — Common Stock (Direct)
Represents shares of common stock subject to restrictions that lapse with respect to 100% of the shares on February 9, 2027. |
Common Stock
|
23 |
| 2026-02-25 | Ornskov Flemming |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
All of the shares of common stock underlying this stock option will vest and become exercisable on February 9, 2027. |
Stock Option (Right to Buy)
|
57 |
| 2026-02-25 | Huang Pearl S |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
All of the shares of common stock underlying this stock option will vest and become exercisable on February 9, 2027. |
Stock Option (Right to Buy)
|
57 |
| 2026-02-25 | Carpio Robert L III |
SVP Waters Analytical Sciences |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The shares of common stock underlying this stock option will vest and become exercisable in four equal annual installments, with the first such installment vesting and becoming exercisable on February 25, 2027, subject to the Reporting Person's continued service with the Issuer on each such vesting date. |
Stock Option (Right to Buy)
|
4,884 |
| 2026-02-25 | Batra Udit |
Director, President and CEO |
Award↑
Filing footnotes — Common Stock (Direct)
Represents restricted stock units ("RSUs"), which will vest in four equal annual installments, with the first such installment vesting on February 25, 2027, subject to the Reporting Person's continued service with the Issuer on each such vesting date. The RSUs are convertible into shares of the Issuer's common stock on a one-to-one basis upon vesting and settlement. |
Common Stock
|
5,165 |
| 2026-02-25 | Huang Pearl S |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
Represents shares of common stock subject to restrictions that lapse with respect to 100% of the shares on February 9, 2027. |
Common Stock
|
23 |
| 2026-02-25 | Vergnano Mark |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
Represents shares of common stock subject to restrictions that lapse with respect to 100% of the shares on February 9, 2027. |
Common Stock
|
23 |
| 2026-02-25 | Carpio Robert L III |
SVP Waters Analytical Sciences |
Award↑
Filing footnotes — Common Stock (Direct)
Represents restricted stock units ("RSUs"), which will vest in four equal annual installments, with the first such installment vesting on February 25, 2027, subject to the Reporting Person's continued service with the Issuer on each such vesting date. The RSUs are convertible into shares of the Issuer's common stock on a one-to-one basis upon vesting and settlement. |
Common Stock
|
997 |
| 2026-02-25 | Batra Udit |
Director, President and CEO |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The shares of common stock underlying this stock option will vest and become exercisable in four equal annual installments, with the first such installment vesting and becoming exercisable on February 25, 2027, subject to the Reporting Person's continued service with the Issuer on each such vesting date. |
Stock Option (Right to Buy)
|
25,283 |
| 2026-02-05 | Bennett Jianqing |
SVP Waters Adv. Diagnostics |
Tax↓
Filing footnotes — Common Stock (Direct)
Represents shares of common stock withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of previously reported restricted stock units. |
Common Stock
|
43 |
| 2026-02-05 | Chaubal Amol |
SVP & Chief Financial Officer |
Tax↓
Filing footnotes — Common Stock (Direct)
Represents shares of common stock withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of previously reported restricted stock units. |
Common Stock
|
58 |
| 2026-02-05 | Carpio Robert L III |
SVP Waters Analytical Sciences |
Tax↓
Filing footnotes — Common Stock (Direct)
Represents shares of common stock withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of previously reported restricted stock units. |
Common Stock
|
38 |
| 2026-02-05 | Batra Udit |
Director, President and CEO |
Tax↓
Filing footnotes — Common Stock (Direct)
Represents shares of common stock withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of previously reported restricted stock units. |
Common Stock
|
218 |
| 2026-02-04 | Bennett Jianqing |
SVP Waters Adv. Diagnostics |
Award↑
Filing footnotes — Common Stock (Direct)
Represents performance-based restricted stock units ("PSUs") originally granted on February 8, 2023, subject to pre-determined service and performance-based vesting requirements. The level of achievement of the performance-based vesting requirement for the PSUs was certified by the Issuer's Compensation Committee on February 4, 2026, and the PSUs will vest in full upon satisfaction of the service-based vesting requirement on March 1, 2026. The PSUs are convertible into shares of the Issuer's Common Stock on a one-to-one basis upon vesting and settlement. |
Common Stock
|
1,385 |
| 2026-02-04 | Batra Udit |
Director, President and CEO |
Award↑
Filing footnotes — Common Stock (Direct)
Represents performance-based restricted stock units ("PSUs") originally granted on February 8, 2023, subject to predetermined service and performance-based vesting requirements. The leve of achievement of the performance-based vesting requirements for the PSUs was satisfied upon the certification by the Issuer's Compensation Committee on February 4, 2026, and the PSUs will vest in full upon satisfaction of the service-based vesting requirement on March 1, 2026. The PSUs are convertible into shares of the Issuer's Common Stock on a one-to-one basis upon vesting and settlement. |
Common Stock
|
7,066 |
| 2026-02-04 | Chaubal Amol |
SVP & Chief Financial Officer |
Award↑
Filing footnotes — Common Stock (Direct)
Represents performance-based restricted stock units ("PSUs") originally granted on February 8, 2023, subject to pre-determined service and performance-based vesting requirements. The level of achievement of the performance-based vesting requirement for the PSUs was certified by the Issuer's Compensation Committee on February 4, 2026, and the PSUs will vest in full upon satisfaction of the service-based vesting requirement on March 1, 2026. The PSUs are convertible into shares of the Issuer's Common Stock on a one-to-one basis upon vesting and settlement. |
Common Stock
|
1,884 |
| 2026-01-02 | FEARON RICHARD H |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
Represents shares of common stock subject to restrictions that lapse with respect to 100% of the shares on January 2, 2027. |
Common Stock
|
307 |
| 2026-01-02 | BADDOUR LINDA |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
Represents shares of common stock subject to restrictions that lapse with respect to 100% of the shares on January 2, 2027. |
Common Stock
|
307 |
| 2026-01-02 | KUEBLER CHRISTOPHER A |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
Represents shares of common stock subject to restrictions that lapse with respect to 100% of the shares on January 2, 2027. |
Common Stock
|
307 |